Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

por Tompson, Debra, Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, Zann, Vanessa, McKenzie, Litza, Abbott-Banner, Kathy, Hawkins, Simon, Powell, Marcy
Publicado 2022

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

por Tompson, Debra J., Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, McKenzie, Litza, Zann, Vanessa, Powell, Marcy, Abbott-Banner, Kathy, Hawkins, Simon
Publicado 2021

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor

por Joshi, Samit R., Fernando, Disala, Igwe, Stephanie, McKenzie, Litza, Krishnatry, Anu S., Halliday, Fiona, Zhan, Joyce, Greene, Thomas J., Xu, Jianfeng, Ferron‐Brady, Geraldine, Lataillade, Max, Min, Sherene
Publicado 2020

Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects

por Jordán, Tamás, Basa-Dénes, Orsolya, Angi, Réka, Orosz, János, Ötvös, Zsolt, Ujhelyi, Andrea, Filipcsei, Genovéva, Molnár, László, Solymosi, Tamás, Glavinas, Hristos, Capone, Dominic, Whitfield, Nicola, McDermott, John, McKenzie, Litza, Shurety, Lauren, Duus, Elizabeth Manning
Publicado 2021